On January 28, 2021, the Guangdong MPA (Medical Products Administration) announced the pilot plan (No.5-2021) to introduce Hong Kong medical devices into the China Greater Bay Area via the University of Hong Kong-Shenzhen Hospital as a start.
In the announcement, the Guangdong MPA addressed the following responsibilities of the different departments involved to support the pilot plan:
| Department | Responsibilities |
| Guangdong MPA | Fully support the pilot phase for the University of Hong Kong-Shenzhen Hospital to use drug and medical device products from Hong Kong and Macao Formulate a review report and recommendation plan after the pilot phase ends on July 31, 2021 |
| Health Commission of Guangdong Province | Implement the internal evaluation process and standard requirements for the approval of GBA medical institutions to use drug and medical device products from Hong Kong and Macao |
Guangdong Provincial Development and Reform Commission | Strengthen the policy implementation and follow up for confirmation |
| Department of Finance of Guangdong Province | Consolidate the designated medical institutions’ requests for import tariff reductions and submit them to the Ministry of Finance for approval |
Guangdong Sub-administration of GACC (General Administration of Customs. P.R. China) | Coordinate with the related customs departments of Hong Kong, Macao and the nine Pearl River Delta municipalities to deliver proper custom clearance procedures |
The pilot plan came into force on January 28, 2021 and will end on July 31, 2021.
By Jacky Li. Contact Cisema if you would like to learn more.
